(Received for publication, December 19, 1996, and in revised form, April 24, 1997)
From the Department of Pathology and Laboratory of Medicine, the University of North Carolina, Chapel Hill, North Carolina 27599-7525, the ¶ Institut Pasteur de Lille U-235, Lille, France, and the ** Department of Medicine, Durham VA Hospital and Duke University Medical Center, Durham, North Carolina 27705
Apolipoprotein (apo) E, a constituent of several
lipoproteins, is a ligand for the low density lipoprotein receptor, and
this interaction is important for maintaining cholesterol and
triglyceride homeostasis. We have used a gene replacement strategy to
generate mice that express the human apoE3 isoform in place of the
mouse protein. The levels of apoE mRNA in various tissues are
virtually the same in the human apoE3 homozygous (3/3) mice and their
littermates having the wild type mouse allele (+/+). Total cholesterol
and triglyceride levels in fasted plasma from the 3/3 mice were not different from those in the +/+ mice, when maintained on a normal (low
fat) chow diet. We found, however, notable differences in the
distribution of plasma lipoproteins and apolipoprotein E between the
two groups: -migrating lipoproteins and plasma apoB100 levels are
decreased in the 3/3 mice, and the apoE distribution is shifted from
high density lipoproteins to larger lipoprotein particles. In addition,
the fractional catabolic rate of exogenously administered remnant
particles without apoE was 6-fold slower in the 3/3 mice compared with
the +/+ mice. When the 3/3 and +/+ animals were fed a high fat/high
cholesterol diet, the 3/3 animals responded with a dramatic increase
(5-fold) in total cholesterol compared with the +/+ mice (1.5-fold),
and after 12 weeks on this same diet the 3/3 animals developed
significantly (at least 13-fold) larger atherosclerotic plaques in the
aortic sinus area than the +/+ animals. Thus the structural differences
between human APOE3 and mouse ApoE proteins are sufficient to cause an
increased susceptibility to dietary-induced hypercholesterolemia and
atherosclerosis in the 3/3 mice.
Apolipoprotein (apo)1 E is important for the transport of cholesterol and triglyceride throughout the body. It is an amphipathic protein that stabilizes the structure of lipoprotein particles via its ability to bind lipid, and it functions as a ligand for lipoprotein receptors, such as the low density lipoprotein receptor (LDLR) and the low density lipoprotein receptor-related protein (1-3). ApoE is a major protein component of chylomicron remnants, very low density lipoproteins (VLDL), and intermediate density lipoproteins (IDL), but it is not present on low density lipoproteins (LDL). ApoE is also enriched in a subclass of high density lipoproteins (HDL) and functions as an effective ligand for their binding to the LDLR (4).
The human APOE gene is located on chromosome 19 (5) as part of an apolipoprotein cluster that also includes the genes encoding APOCI, APOCII, and APOCIV (6). Multiple tissue-specific enhancers and negative elements have been identified in the region proximal to the gene (7). A distal enhancer, the hepatic control region, that is required for liver expression is located 15 kb downstream of the gene (8, 9). The liver synthesizes approximately 70% apoE found in the body and 20% is found in the brain, and the remainder is synthesized in several tissues including the spleen, lung, heart, ovary, testis, kidney, and skin (10, 11).
Three major APOE alleles, 2,
3, and
4, occur in
humans at frequencies of 7.3, 78.3, and 14.3%, respectively (12).
These three alleles are distinguished by coding differences at
positions 112 and 158 (13). The most common isoform, apoE3, has a
cysteine at position 112 and an arginine at position 158; the apoE2
isoform has a cysteine at both positions, whereas the apoE4 isoform has an arginine at both positions. Functionally, the three isoforms differ
in their affinity for the LDLR, with apoE3 and E4 exhibiting 100%
binding and apoE2 displaying only 1% normal binding affinity (14).
Despite the lower affinity of apoE2 for the LDLR, individuals homozygous for
2 typically have lower than normal plasma cholesterol levels, except for the fraction of homozygotes (5-10%) who develop type III hyperlipoproteinemia (15). Individuals homozygous for
4
have higher total plasma cholesterol and LDL cholesterol compared with
3 homozygotes and are at increased risk for developing coronary artery disease (16). The
4 allele is also associated with the development of Alzheimer's disease (17, 18).
ApoE isoform-specific effects are important in the etiology of atherosclerosis and other diseases, but appropriate animal models to rigorously investigate these effects are currently lacking. To date, transgenic animals made by pronuclear injection of human DNA have been used to study these effects, but this method produces mice with varying levels of transgene expression due to differences in chromosomal location and copy number, and expression of the endogenous mouse apoE complicates the interpretation of the data (19-24, 47). To overcome these difficulties we have used targeted gene replacement to generate mice that express only the human apoE3 isoform at levels that are in the physiological range. In these mice the coding sequences for mouse apoE were replaced with sequences coding for human APOE3 without disturbing any of the known regulatory sequences. This replacement results in animals with expression of human apoE mRNA, identical in tissue distribution and levels, to that of mouse apoE mRNA in wild type animals.
We here describe the essentially normal cholesterol and triglyceride levels of mice homozygous for human apoE3 (3/3) when maintained on a normal (low fat) mouse chow diet but show that they are markedly more susceptible to diet-induced atherosclerosis than their wild type littermates (+/+).
The targeting construct was made by
inserting into a pPNT vector (25), a 4.1-kb SacI human
genomic fragment isolated from a plasmid, pHEG-1 (20), kindly provided
by Dr. John Taylor at the University of California, San Francisco. This
fragment contains the 3 part of intron 1 (723 base pairs), exons 2-4
of the human APOE3 gene, and 1.5 kb of 3
-flanking DNA. A
5.3-kb EcoRI-SacI strain 129 mouse genomic
fragment containing sequences upstream of the mouse apoE
gene including exon 1 and the 5
part of intron 1 (376 base pairs) was
inserted 5
to the human APOE3 fragment. A 1.4-kb
PvuI-KpnI strain 129 mouse genomic fragment
containing the 3
-half of exon 4 and 3
-flanking sequence was inserted
downstream of the neomycin-resistant gene in pPNT (see Fig. 1,
below).
Generation of Homozygous Human apoE3 Mice
A subclone (BK4) of mouse strain 129 embryonic stem (ES) cell line, E14TG2a, was cultured and electroporated with the human apoE3 targeting construct as described previously (26). Targeted ES cell clones were identified by Southern blot analysis. Chimeras were generated and mated with C57BL/6J (B6) mice. F2 generation mice were used for all of the experiments described. Mice were kept on a normal (low fat) chow diet consisting of 5% (w/w) fat and 0.022% (w/w) cholesterol (Prolab RMH 3000, number 5P76, St. Louis, MO) or on an atherogenic diet that contains 15.8% (w/w) fat, 1.25% (w/w) cholesterol, and 0.5% (w/w) sodium cholate (TK 88051, Teklad Premier, Madison, WI).
Plasma Lipid MeasurementsAll lipid measurements were performed on mice between the age of 8 and 20 weeks. Animals were fasted overnight (approximately 16 h), anesthetized with Avertin, and 150 µl of blood was collected from the retro-orbital sinus into tubes containing 8 mM EDTA, 1 µg/ml aprotinin (Boehringer Mannheim), and 1 µg/ml gentamycin, and stored on ice. Plasma was removed after centrifugation at 8,000 × g for 10 min at 4 °C, and total cholesterol and HDL cholesterol were measured using diagnostic CII kits (Wako, Richmond, VA) according to the manufacturer's instructions. Triglyceride levels were measured using an enzymatic kit (Sigma).
Plasma Lipoprotein AnalysisWithin 1 h of blood collection, 1 µl of plasma was electrophoresed in precast 1% agarose gels (Ciba Corning Diagnostics Corp., Palo Alto, CA), and neutral lipids were visualized by Fat Red 7B staining (Sigma). One ml of pooled plasma from 10 mice (100 µl each) was separated by sequential density ultracentrifugation into seven fractions ranging in densities from <1.006 g/ml to >1.21 g/ml, using the procedure described by de Silva et al. (27). Total lipoproteins were isolated from plasma at a density <1.21 g/ml. Lipoprotein fractions were dialyzed against 10 mM Tris, pH 7.4, 1 mM EDTA, 150 mM NaCl before electrophoresis in a 3-20% denaturing SDS-PAGE gel (27). Plasma (100 µl) from either individual or pooled samples were separated by gel filtration chromatography using a Superose 6 HR10/30 column (Pharmacia Biotech Inc.). Immunoblot analysis of FPLC fractions (2 µl) electrophoresed in precast 1% agarose gels was performed with antibodies described below.
Northern Blot AnalysisTotal RNA was extracted from several tissues according to the method of Chomczynski and Sacchi (28) using RNAzolTM B (Tel-test, Friendswood, TX). Total RNA (20 µg) was electrophoresed in a 1% agarose gel after denaturation with a glyoxal/Me2SO mixture (29). RNA was transferred to a Hybond membrane (Amersham Corp.) and hybridized overnight at 42 °C in 50% formamide, 5 × SSC, 1 × Denhardt's solution, 100 µg of salmon sperm DNA, 30 mM sodium phosphate, pH 6.5, and 10% dextran sulfate; the probe was a mouse exon 4 DNA fragment labeled with [32P]dCTP. The blot was washed in 3 × SSC, 0.1% SDS for 10 min at 37 °C and then 0.1 × SSC, 0.1% SDS for 10 min at 65 °C. The blot was exposed to preflashed Kodak XAR film for 20 h.
ApoE Enzyme-linked Immunosorbent AssayHuman APOE in mouse
plasma was measured with a sandwich-type enzyme-linked immunosorbent
assay (ELISA) essentially as described (30). A mouse anti-human apoE
monoclonal antibody, E01 ( huE (m)) (30), was used as the capture
antibody and a goat anti-human apoE antibody (
huE (p)) (Calbiochem)
as the detecting antibody. The
huE (p) antibody cross-reacts with
mouse apoE at a low level. The
huE (m) antibody has been shown to
react with human APOE in all classes of lipoprotein particles (30) and
does not cross-react with mouse ApoE. Values were determined with a
standard curve made with pooled human plasma whose apoE levels were
determined against purified recombinant human apoE3 (number 178475, Calbiochem) and validated against an international calibrator (Dr. N. Rifai, Childrens Hospital, Boston, MA).
Mouse ApoE was measured in a similar manner using a purified rabbit
anti-mouse apoE antibody ( muE (m)) (10 µg/ml) raised against a
mouse apoE peptide (residues 179-241) for the capture antibody. The
same antibody conjugated to horseradish peroxidase was used for
detection with chromagen. The mouse peptide (residues 179-241) was
used as a standard for determining the concentration of mouse ApoE.
Fasted whole plasma (1 µl) was electrophoresed in a 4-20% denaturing SDS-PAGE gel or in a 1% agarose gel, transferred to an Immobilon P membrane (Millipore Corp., Bedford, MA), and reacted with all three anti-apoE antibodies described above. Immunoreactive proteins were visualized with a horseradish peroxidase conjugate using an enhanced chemiluminescence kit (Amersham Corp.). Western blots for the analysis of apoB were made similarly using 4% SDS-PAGE and rabbit anti-mouse apoB sera (gift from Dr. Steven Young, University of California, San Francisco).
Clearance AssayFour apoE (/
) mice were injected with
20 µg of free cholesterol containing 2.5 µCi of
4-14C-labeled cholesterol dispersed in an egg lecithin/free
cholesterol (1:1 molar ratio) mesophase. The apoE (
/
)
-VLDL
fraction was isolated 36 h later by centrifugation at 1.010 g/ml.
More than 72% of the tracer was in the cholesterol ester fraction
(31). Three mice in each group (apoE
/
, 3/3, and +/+) were injected with the labeled apoE (
/
)
-VLDL. The fractional catabolic rates and their variances were determined up to 4 h as described
previously (31).
Female mice that had been fed a high fat diet for 3 months were sacrificed by Avertin overdose after a 16-h fast. The thoracic cavity was opened, and the heart and vascular system were perfused with 4% paraformaldehyde in phosphate-buffered saline, pH 7.4, under physiological pressure. Segments of the proximal aorta and aortic sinus were embedded, sectioned, and stained as described previously (32). Morphometric evaluations of lesion size were made using the NIH image (version 1.41) software.
Statistical AnalysisThe significance of differences between means was tested by using a two-tailed unpaired Student t test or a nonparametric Mann-Whitney U test.
The targeting strategy used to replace the mouse apoE
coding exons 2-4 with the human counterpart is illustrated in Fig.
1. Homologous recombination between the targeting
construct (Fig. 1B) and the endogenous mouse apoE
locus (Fig. 1A) results in a chimeric gene (Fig.
1C) where all the mouse coding sequences have been replaced
with sequences coding for human APOE3. This chimeric locus
retains all normal mouse regulatory sequences in addition to the
non-coding mouse exon one. Identification of correctly modified
embryonic stem (ES) cells was by Southern blot analysis with a mouse
exon 1 or exon 4 probe (data not shown); ES cell DNA digested with
EcoRI and hybridized with the mouse exon 1 probe revealed an
8.3-kb endogenous band and a 7.8-kb targeted band confirming the
correct modification of the 5 region; ES cell DNA digested with
HindIII and hybridized with mouse exon 4 probe revealed a
7.5-kb endogenous band and a 15-kb targeted band confirming correct
modification of the 3
region. The modified locus was transmitted to
the F1 generation from chimeras that were made from one of the targeted
cell lines. All F1 matings produced normal litter sizes with a normal
Mendelian segregation pattern of the modified locus. Genotypes of F2
animals were determined using Southern blot analysis of tail DNA
digested with BamHI (Fig. 2A). The
nucleotide sequence for codon 112 (TGC) and codon 158 (CGC) in a 3/3
mouse was confirmed using allele-specific PCR (33) on tail DNA.
Human apoE3 Levels in Whole Plasma
To confirm the presence of
human APOE protein in the mice, plasma (1 µl) from 3/3, 3/+, +/+
mice, and a human (hu) were electrophoresed in a 4-20% gradient
denaturing SDS-PAGE gel. Western blot analysis with anti-human apoE
antisera ( huE (p)), which slightly cross-reacts with mouse ApoE,
showed that human APOE (34, 200 Da) in 3/3 plasma migrates at the same
rate as apoE in human plasma and slightly slower than the mouse apoE
(32, 600 Da) in +/+ plasma (Fig. 2B). The absence of mouse
ApoE in the 3/3 plasma was confirmed by Western blot analysis with an
anti-mouse apoE antibody (
mu (m)), which shows that mouse ApoE is
present only in the +/+ and 3/+ samples and not in the 3/3 plasma. In
contrast, the anti-human apoE monoclonal antibody (
huE (m)), which
does not cross-react with mouse ApoE, shows that human APOE was present
only in 3/3, 3/+, and human plasma and not in the +/+ plasma (Fig.
2B). Western blotting of plasma from two 3/3 mice in a
4-20% nonreducing SDS-PAGE gel showed that human APOE3 homodimer was
present at less than 5% monomeric E3 (Fig. 2C).
The concentration of apoE in 3/3 plasma (1.30 ± 0.47 mg/dl) as determined by ELISA was very similar to the levels (1.13 ± 0.23 mg/dl) found in +/+ plasma (see Table I below).
|
Total RNA was extracted
from several tissues including skin (Sk), spleen
(Sp), kidney (Ki), small intestine
(Si), stomach (St), heart (He), testis
(Te), muscle (Mu), lung (Lu), liver
(Li), submandibular gland (Su), and brain
(Br) from a 3/3 male mouse and a wild type +/+ male mouse.
Northern blot analysis with a mouse exon 4 probe was used to compare
the levels of apoE mRNA in the two types of animal (Fig.
3). This probe hybridizes equally well to the human gene
and the mouse gene under the conditions used. A -actin probe was
hybridized to the same blot after removal of the apoE probe
(lower panels in Fig. 3) to assess the amount of mRNA
loaded in each group. In agreement with previous reports (10, 11) apoE
mRNA expression was highest in the liver and second in the brain,
with lesser amounts in other tissues. No apoE mRNA was detected in
muscle. The expression of apoE mRNA in the 3/3 and +/+ animals was
essentially indistinguishable in all tissues analyzed, with the
exception of small intestine which had reduced levels of apoE mRNA
in the 3/3 animals compared with +/+ mice. This Northern blot analysis
clearly demonstrates that the modified locus containing human apoE3
coding sequences and the wild type mouse gene are expressed at
virtually identical levels in all tissues.
Plasma Lipids and Lipoproteins in Mice Fed Normal Chow
The levels of total cholesterol (TC), triglycerides, and HDL cholesterol in female mice fed a normal (low fat) chow diet were determined in plasma obtained after a 16-h fast (Table I). There was no difference in TC levels between the 3/3 mice (67 ± 18 mg/dl, n = 30) and the +/+ controls (73 ± 20 mg/dl, n = 30), in striking contrast to the total cholesterol levels previously found in apoE-deficient mice on the same diet (541 ± 220 mg/dl, 32). The TC levels in males were higher than females (p = 0.0001), but again there were no differences between the 3/3 and the +/+ group. Triglyceride and HDL cholesterol levels in the 3/3 mice and the +/+ mice were also very similar (Table I).
Fasted wild type (+/+) plasma lipoproteins migrate as three distinct
bands designated (HDL),
(LDL), and pre-
(VLDL) using agarose
gel electrophoresis (Fig. 4A). Plasma from
fasted 3/3 mice, on the other hand, showed an increase in the pre-
band and the absence of
-migrating lipoproteins relative to the +/+ samples. These differences were observed in the plasma of both male and
female 3/3 mice. The amount of
-migrating particles in the 3/3 and
+/+ mice were the same. These results suggest that the 3/3 mice have
slightly increased amounts of VLDL/IDL remnants and a reduction of LDL
particles.
To determine the amount of apoB100 relative to apoB48, equal amounts of whole plasma from a 3/3 and a +/+ female mouse were separated in a 4% SDS-PAGE gel, blotted, and reacted with anti-mouse apoB sera (Fig. 4B). A densitometric scan of the autoradiograph showed that the 3/3 sample had a B100:B48 ratio of 1:3 compared with a B100:B48 ratio of 1:0.8 in the +/+ sample. In a separate experiment total lipoproteins (density <1.21 g/ml) were isolated from pooled plasma from five female 3/3 mice and four +/+ mice and electrophoresed in a 3-20% SDS-PAGE gel. Coomassie Brilliant Blue staining of the gel (Fig. 4C) showed that plasma apoB100 levels in the 3/3 mice were greatly reduced compared with the +/+ mice and that apoB48 levels were higher in the 3/3 mice compared with the +/+ mice.
Different Distribution of Human and Mouse Apolipoprotein EIndividual plasma samples and pooled (n = 10)
plasma samples were separated by gel filtration chromatography on a
Superose 6B column for the determination of cholesterol,
triglyceride, and apoE distribution. The distribution of
cholesterol (solid circles in Fig. 5,
A and B) was nearly identical for
the 3/3 and +/+ mice except for a small decrease in fractions 21-24 in
the 3/3 group. This decrease in LDL cholesterol agrees with the agarose gel electrophoresis results described above. Triglyceride distribution was essentially the same for both groups (data not shown) with the
largest percentage of triglyceride present in fractions 14-16.
Contrary to the identical distribution of lipids, the distribution of
apoE (open circles in Fig. 5, A and B)
in the 3/3 and +/+ mice was markedly different as determined by ELISA
with mouse- and human-specific antibodies. The majority of apoE in +/+
mice is present in the HDL region (fractions 26-31) with only a minor amount present in the VLDL (fractions 14-17) and IDL-LDL regions (fractions 18-25) (Fig. 5B). Western blot analysis of +/+
FPLC fractions electrophoresed in an agarose gel using the -huE (p) antisera support the results obtained by ELISA (Fig. 5D).
However in the 3/3 mice the majority of apoE is present in two very
distinct peaks where VLDL (fractions 14-17) and IDL species (fractions 18-21) typically elute (Fig. 5A). Western blots of an
agarose gel with each FPLC fraction are in agreement with the apoE3
distribution as determined by ELISA (Fig. 5C). SDS-PAGE gel
electrophoresis of lipoproteins fractionated by sequential density
ultracentrifugation (Fig. 6A) showed that
apoE3 in the 3/3 mice was found predominantly in the lower density
fractions, d < 1.04 g/ml. No major differences were
detectable in the distributions of apolipoproteins AI in the 3/3 and
+/+ samples and the apoC's after SDS-PAGE of fractions separated by
sequential density ultracentrifugation (Fig. 6A).
The IDL-like peak in 3/3 plasma is particularly noteworthy since
cholesterol and triglyceride in these fractions are very low. These
IDL-like particles, enriched in apoE3, most likely represent
VLDL/chylomicron remnants since agarose gel electrophoresis of FPLC
fractions followed by Western blotting with huE (p) antisera
demonstrated that the majority of apoE3 was associated with particles
migrating at the pre-
-position, and association of apoE3 with large
HDL particles at the
-position was minimal (Fig. 5C).
FPLC analysis of plasma after immunoprecipitation with an anti-mouse
apoB antibody confirms that the IDL-like particles contain apoB (data
not shown). Interestingly, FPLC analysis of plasma from mice
heterozygous for human apoE3 (3/+) showed a shift of the second apoE3
peak to fractions 21-25, suggesting that the co-presence of mouse ApoE
reduces the size of remnant particles where apoE3 accumulates (data not
shown). An increase in mouse ApoE, associated with larger particles, is
also evident in the heterozygote although approximately half of mouse
ApoE was still found associated with HDL.
The same 3/3
(n = 12) and +/+ (n = 12) female mice
used to measure lipid profiles on normal chow were fed an atherogenic
diet for 8 weeks to assess any change in response to diet between the two groups. One +/+ animal showed significant weight loss with a yellow
colored plasma during the diet study and was excluded. The 3/3 mice
responded with a 5-fold increase in cholesterol (350 ± 207 versus 67 ± 18 mg/dl), whereas the cholesterol in
control mice increased about 1.5-fold (111 ± 44 versus
73 ± 20 mg/dl) (Table I). Triglyceride levels in the 3/3 and +/+
mice were reduced by 18 and 50%, respectively. HDL cholesterol levels
were reduced in both groups of mice to about the same extent
(approximately 50%). Agarose gel electrophoresis of plasma from both
types of animals showed a decrease in -migrating particles and an
increase in pre-
-migrating particles consistent with total lipid
measurements (data not shown). These results suggest that there is a
marked increase in remnant particles with concurrent reduction in HDL in response to the atherogenic diet in both types of mice, but the
extent of increase in the 3/3 mice is much larger.
The elution profile in a Superose 6 gel filtration column of 3/3 plasma
(Fig. 7A) showed that the majority of the
(highly elevated) cholesterol was in the VLDL-IDL fractions, whereas in the +/+ group (modestly increased) cholesterol was distributed equally
between the VLDL and HDL fractions (Fig. 7B). As expected in
the +/+ mice, the distribution of apoE followed that of cholesterol (Fig. 7B). The apoE distribution pattern in the 3/3 animals
was highly unusual and was similar to that seen when the same animals were fed a normal chow diet; again two distinct classes of lipoproteins in the VLDL and IDL range were associated with human APOE (Fig. 7A). There was a large increase in plasma apoE in the 3/3
animals (10.80 ± 5.60 versus 1.30 ± 0.47 mg/dl)
compared with no increase in the +/+ animals (1.11 ± 0.34 versus 1.13 ± 0.23 mg/dl) between the two diets (Table
I).
The distributions of several other plasma apolipoproteins were also different between the 3/3 and +/+ mice fed the high fat diet (Fig. 6B). A comparison of the apolipoprotein distribution among density fractions by SDS-PAGE in Fig. 6, A (normal chow) and B (high fat), revealed a marked increase on the high fat diet of apoE, AI, and AIV mainly in the 1.006-1.04 g/ml fractions in the +/+ mice. In contrast the 3/3 mice showed increases in these proteins over the whole density range. Of particular interest is the increase of apoAI in the 1.006 < d < 1.04 fraction, and apoAIV in the 1.04 < d < 1.06 fraction in the 3/3 mice. The amount of apoB48 was increased in the 3/3 mice compared with +/+ mice, but their distribution was not different.
Delayed Clearance of apoE-deficientThe
marked increase of cholesterol-rich remnant particles seen in the 3/3
animals in response to an atherogenic diet suggests that human apoE3 is
not as effective as its murine homologue in the clearance of these
particles in mice. To test this possibility, we injected
14C-radiolabeled remnant particles (>72% cholesterol
ester) in the -VLDL flotation range (prepared from apoE-deficient
mice) into mice fed normal chow and measured the decay of label over a
4-h period. The decay of [14C]cholesterol was rapid in
the +/+ mice and virtually complete in 15 min (Fig. 8).
The fractional catabolic rate in +/+ mice based on a single compartment
system was 0.12 ± 0.002/min. Clearance of the same lipoproteins
in apoE (
/
) mice was considerably slower, with a fractional
catabolic rate of 0.005 ± 0.0003/min. The 3/3 mice had a rate
(0.02 ± 0.0003/min) 6-fold slower than +/+ mice but more rapid
than the apoE (
/
) mice. Note, however, that within 2 h the
amount of label remaining in the 3/3 mice had decreased to the same
levels seen in the +/+ mice.
Morphometric Evaluations of Aortic Lesions
After 3 months on
an atherogenic diet, 3/3 and +/+ animals (all females) were evaluated
for atherosclerotic lesions. All measurements were made from sections
in the proximal aorta near the aortic valve attachment sites. All six
3/3 animals developed substantial atherosclerotic lesions with a
logarithmic mean area of 6.4 × 104 µm2
(ranging from 2.4 × 104 to 16.8 × 104). In contrast four out of five +/+ animals developed
fatty streak lesions that were small, with a logarithmic mean area of
5.1 × 103 µm2 (ranging from 2.9 × 103 to 9.2 × 103) (Fig.
9). One +/+ animal had no lesions. These observations clearly demonstrate that the 3/3 mice are much more susceptible to
diet-induced atherosclerosis than +/+ mice.
We have successfully replaced the coding sequence of the mouse apoE gene with the equivalent human APOE3 coding region without altering any known endogenous regulatory sequences. Expression of the human apoE mRNA in the liver, brain, and other tissues parallels that found normally in wild type mice. Thus, the human APOE3 protein is functional and is expressed at physiological levels in these modified mice, thereby providing a model for studying the function of human APOE3 in vivo.
To date, pronuclear injection of DNA has been used to generate transgenic animals expressing various forms of human APOE to study its role in lipid metabolism (19-24, 47). There are three severe limitations to this approach as follows: the number of copies of the transgene can vary over wide ranges; there are marked and uncontrolled differences in the expression of transgenes at different chromosomal locations; and the presence of the endogenous mouse protein complicates the interpretation of the results. Most importantly, rigorous comparisons between different isoforms are not possible because of the variable expression inherent in conventional transgenic animals.
Mice made by replacement of the endogenous mouse coding region with the equivalent region of the human gene retain the natural chromosomal context at the apoE locus. Thus, locus-specific sequences and enhancers are not altered except for any possible intragenic control sequences that differ between mice and humans. Therefore, it was expected that tissue-specific expression of the human replacement APOE3 gene would closely parallel that of the endogenous mouse apoE gene. Our mRNA studies show that this expectation was indeed fulfilled, with the exception of intestinal apoE mRNA which was slightly reduced in the 3/3 mice compared with the +/+ mice. The significance of this reduction in intestinal expression is not clear, considering that intestinal apoE expression is very low compared with other tissues and that chylomicrons originating from the small intestine are known to contain very little apoE (34, 35). Differences between the 3/3 and +/+ mice consequently are highly informative as far as function of the apolipoprotein itself are concerned. Thus, gene replacement demonstrates the advantages over pronuclear injection in generating transgenic animals.
The lipid profiles of the 3/3 and +/+ mice are very similar when the mice are maintained on a chow (low fat) diet, and the fasting levels of total cholesterol, triglyceride, and HDL cholesterol are essentially identical in the two animals. However, when the same mice were fed a high fat diet, the 3/3 animals responded with a 5-fold increase in total cholesterol compared with a 1.5-fold increase in the +/+ animals. Second, after 3 months on a high fat diet, the atherosclerotic plaques seen in all the 3/3 animals were 13-fold larger than those observed in the wild type controls. Third, there was a 6-fold slower clearance rate of remnant lipoprotein particles in the 3/3 animals. The accumulation of cholesterol and the delayed clearance of remnant particles observed in the 3/3 animals are likely causes of the increased susceptibility to lesion development.
The dramatic delay in clearance of remnant particles in the 3/3 mice was unexpected since previous studies using transgenic mice expressing human APOE have revealed normal or enhanced clearance kinetics (22, 36). One possible explanation for the observed delay in clearance is that the human APOE3 protein has a lower affinity to mouse LDLR and/or other receptors than mouse ApoE because of species differences in their structures. Mouse and human apoE differ in 30% of their amino acid sequences with most of the differences being at the amino and carboxyl termini (1). The receptor binding domain (residues 136-160) is highly conserved between mouse and human apoE since 21 of 25 residues are identical in this region including seven residues designated as critical for receptor binding (37, 38). The residues that differ have conservative substitutions (e.g. methionine for leucine) that do not affect the net charge or hydrophobicity of the protein and would not be predicted to have any substantial effects on the protein conformation (39). Thus, it must be ascribed to differences outside the receptor binding domain if the affinity for the receptor differs between the mouse and human apoE proteins. Species differences in the receptors that interact with apoE, such as the LDLR, and low density lipoprotein receptor-related protein, could also contribute to a lower affinity.
A dysfunctional interaction between human APOE3 and mouse heparan sulfate proteoglycans (HSPG) may also contribute to the delay in clearance. It has been postulated that HSPG's are involved in the initial sequestration process that enhances the uptake of apoE containing lipoproteins (40, 41). The interaction of apoE with HSPG's is thought to occur mainly via electrostatic attraction (42). Human APOE3 has a cysteine at position 112 where the mouse protein has an arginine at the equivalent position (mouse apoE residue 104). This charge difference could be significant, even though residue 112 is outside the known heparin-binding domain.
The delayed clearance could also be due to protein-protein interactions not involving receptors. Several proteins are known to interact with apoE and play a role in lipid metabolism. For example, the interaction of apoE with hepatic and lipoprotein lipases mediates/or enhances the catabolism of lipoproteins (41). Lipoprotein particles containing human APOE3 may be less efficient in this type of interaction than mouse ApoE. This would have important consequences in the remodeling and processing phase of lipoprotein catabolism.
Another consideration in the clearance experiment is that the exogenously introduced remnant particles have to acquire apoE prior to their removal by receptors. In +/+ mice most of the plasma apoE is associated with HDL particles that are presumably the source of apoE used to clear the exogenously added remnants. In the 3/3 animals, however, the majority of plasma apoE3 is associated with large lipoproteins and may not transfer as easily to exogenously added particles. In support of this, we and others (27) have noted that the distributions of apoE among mouse plasma lipoproteins analyzed by FPLC and by ultracentrifugation do not always agree and that apoE associated with HDL are more readily lost by ultracentrifugation. Although the capacity for apoE3 to exchange between different classes of lipoproteins has not been documented, the decreased ability of apoE3 to transfer from large lipoproteins may have important implications.
The association of apoE3 with larger lipoproteins in mice (Fig. 5,
A and C) is different from observations made in
humans that demonstrate a preference of apoE3 for HDL (1, 43). It is
very unlikely that this difference is the result of a mutation unexpectedly introduced into the APOE3 gene during its
manipulation because in our work2 we
observed that transgenic apoE3 mice, in an endogenous apoE (/
)
background, had a virtually identical apoE3 distribution pattern as
seen in the 3/3 replacement mice. These mice were made by pronuclear
injection of a human cosmid clone isolated from a different individual
from the one we used to make our mice (24). Similar findings were also
reported by Taylor et al. (44) in transgenic apoE3 mice
(that also express mouse apoE) which showed that the majority of human
APOE3 resided in larger lipoprotein particles using SDS-PAGE immunoblot
analysis of fractions separated by sequential density
ultracentrifugation. In this work the authors also found that mouse
ApoE and human APOE co-distributed among lipoproteins. This is
different from the results of our FPLC analysis of 3/+ heterozygote
plasma which shows that approximately half of the mouse ApoE and only a
minor fraction of human APOE3 was associated with HDL (data not shown).
It is not known whether the observed differences between our work and
Taylor et al. are the result of different techniques used to
fractionate the plasma lipoproteins or the result of different levels
of human APOE and mouse ApoE expression in the two types of mice.
Further characterization of these large apoE3-rich lipoprotein
particles is required to understand the observed delay in clearance in
the 3/3 animals.
The reduced clearance rate of remnant particles in the 3/3 mice,
whatever its cause eventually proves to be, is not sufficient to cause
any alteration in fasted plasma cholesterol levels in these animals
relative to their +/+ littermates when the animals are on a normal chow
diet. The 3/3 mice are, however, much more susceptible to diet-induced
hyperlipidemia and atherosclerosis than their +/+ littermates.
Possibly, on the high fat diet a postprandial accumulation of
-VLDL's occurs that leads to the development of atherosclerosis, as
suggested by Zilversmit (45). In human APOE2 homozygous
individuals with type III hyperlipoproteinemia, there is an abnormal
accumulation of remnant particles that has been suggested to cause
accelerated coronary and peripheral vascular disease (46). Even small
changes in lipid metabolism that decrease the clearance efficiency of
lipoproteins are likely to have dramatic effects on the development of
atherosclerosis, and thus the 3/3 animals give us an opportunity to
investigate what changes are important.
In conclusion, we have demonstrated the use of targeted gene replacement to generate mice expressing the most common human isoform, APOE3, at physiological levels. These mice allow us to document the behavior of the human APOE3 isoform in vivo in mice without any co-expression of mouse apoE. Future experiments comparing these mice with mice expressing the human apoE2 and E4 isoforms created in an identical manner should prove invaluable for studying diseases related to the different human apoE isoforms.
We thank Dr. Masahiko Watanabe for his help in building the targeting construct and Daniel Throckmorton, Brian Oswald, Denise Lee, and Kim Kluckman for their technical help. We also thank Dr. J. Taylor for the apoE3 plasmid, Dr. J. C. Fruchart for the E01 antibody, Dr. S. Young for the anti-mouse ApoB sera, Dr. N. Rifai for validation of our human apoE standard, and Dr. O. Smithies, Dr. H. deSilva, and Dr. S. Kirby for reviewing the manuscript.